Advertisement

Topics

ViiV Healthcare seeks European marketing nod for single─tablet, two─drug regimen of dolutegravir & lamivudine to treat HIV

06:07 EDT 15 Sep 2018 | PharmaBiz

ViiV Healthcare has announced submission of a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for a single─tablet, two─drug regimen of dolutegravir (DTG) and lamivudine (3TC) for the treatment of HIV─1 infection.

Original Article: ViiV Healthcare seeks European marketing nod for single─tablet, two─drug regimen of dolutegravir & lamivudine to treat HIV

NEXT ARTICLE

More From BioPortfolio on "ViiV Healthcare seeks European marketing nod for single─tablet, two─drug regimen of dolutegravir & lamivudine to treat HIV"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Reverse Transcriptase
Reverse transcriptase (RT) is an enzyme used to generate complementary DNA (cDNA) from an RNA template, a process termed reverse transcription. It is mainly associated with retroviruses. RT inhibitors are widely used as antiretroviral drugs. RT activitie...